Sutro Biopharma (STRO) Interest Expenses (2017 - 2022)

Sutro Biopharma has disclosed Interest Expenses across 6 years of filings, most recently posting $2.8 million for Q3 2022.

• Interest Expenses for Q3 2022 came in at $2.8 million, up 240.0% year-over-year; the trailing twelve-month figure through Jun 2023 was $2.8 million (up 3.91% YoY), and the FY2021 annual result was $3.1 million, down 23.06% from the prior year.
• Interest Expenses came in at $2.8 million for Q3 2022 at Sutro Biopharma, up from $594000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $3.0 million in Q2 2020 to a low of -$2.3 million in Q4 2020.
• The 5-year median for Interest Expenses is $820000.0 (2021), against an average of $805947.4.
• Across the five-year window, Interest Expenses jumped 343.0% in 2019 and plunged 375.52% in 2020, its largest moves.
• Sutro Biopharma's Interest Expenses stood at -$649000.0 in 2018, then jumped by 225.89% to $817000.0 in 2019, then slumped by 375.52% to -$2.3 million in 2020, then surged by 127.19% to $612000.0 in 2021, then surged by 355.56% to $2.8 million in 2022.
• The last three Interest Expenses figures came in at $2.8 million (Q3 2022), $594000.0 (Q2 2022), and $657000.0 (Q1 2022), per Business Quant data.